Table 1 Patient demographics and baseline characteristics

From: Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: a randomised parallel-group study

 

Ciclesonide (N=75)

Budesonide (N=75)

P value

Gender, F (%)

38 (50.7)

35(46.7)

0.624

Age, years

51.2±18.3

55.5±15.4

0.125

Body height, cm

160.0±9.4

161.1±8.0

0.426

Body weight, kg

62.8±9.8

66.0±13.4

0.092

BMI, kg/m2

24.5±3.3

25.4±3.3

0.195

Smoking status

  

1.000

 Nonsmoker, n (%)

66 (88.0)

65 (86.7)

 

 Ex-smokers, n (%) a

9 (12.0)

10 (813.3)

 

Pulmonary function

 FVC, l

2.9±1.1

2.9±0.9

0.942

 FVC, pred. %

92.3±20.1

92.1±21.5

0.958

 FEV1, l

2.2±0.9

2.1±0.7

0.424

 FEV1, pred. %

82.6±19.8

81.6±19.0

0.744

 FEV1/FVC, %

74.6±12.1

71.9±12.0

0.173

 MMEF, l/s

1.9±1.2

1.7±0.9

0.075

Initial diagnosis of asthma

 FVC, l

2.4±0.8

2.4±0.7

0.929

 FVC, pred. %

74.3±15.4

74.7±15.6

0.868

 FEV1, l

1.6±0.6

1.6±0.5

0.776

 FEV1, pred. %

59.5±13.0

59.9±16.8

0.885

 Change of FEV1, % b

22.9±7.6

22.4±7.3

0.661

 FEV1/FVC, %

67.6±11.3

59.9±16.8

0.399

ACT score

24.0±1.0

24.0±0.9

0.867

Previous medicine

 Seretide, %

66 (88.0)

62 (82.7)

0.356

 Symbicort, %

9 (12.0)

13 (17.3)

 
  1. Abbreviations: ACT, asthma control test; F, female; FEV1, forced expiratory volume in 1 s; FVC, forced expiratory capacity; MMEF, maximum mid-expiratory flow; pred., predicted value.
  2. aSmoking history was less than 10 pack-years.
  3. bFEV1 was obtained 15 minutes after inhaled salbutamol (400 μg). Data are expressed as mean±s.d. or number (%).
Back to article page